Entreprise en démarrage développant des inhibiteurs de SEMA 3A - Startup company developing SEMA 3A inhibitors / Dr Mike Sapieha HMR, Montreal, Québec, Canada
@tedcruz The blind leading the blind comes to mind with yet another ridiculous quote from a US politician that clearly has no idea of what is happening in the real world.
Synthetic #cannabinoid#CB1 receptor blockers poised for a comeback after #Montreal based @inversago pharma announces $7M Series A funding. #T1D#PWS#Lifesciences https://t.co/cPaYg2L5Su.
The Lumira Ventures team is pleased to welcome to Veteran Life Sciences Executive Jason D. Hanson to enGene as the company's new Chief Executive Officer and President #lumiraventures https://t.co/4NBHfoKg2E
Lumira Ventures portfolio company Antiva Biosciences completes $15 Million Series C-1 financing with Hillhouse Capital, Sirona Capital and existing investors including Canann, Sofinnova, Brace Pharma, Osage and Lumira - https://t.co/ezT0Aerd3p
"AI-enabled tools will quickly feel invisible, making way for a more personal doctor-to-patient experience. #AI can empower clinicians to do their best work by freeing up their attention to do what only a human can."
Look into the future courtesy... https://t.co/LA9HokDOT5
Second session: Study case of SpecificiT Pharma Inc. @PierreBeauparlant CEO of SpecificiT, Grazia Maion from @univalor, Alain Dumont from GGD, Ines Holzbaur @AmorChem
SEMA 3A was identified as a novel target for ocular diseasesthat promotes vascular leakage and contributes to diabetes-related macular edema. https://t.co/qHU7j3PfCi #Diabetes#DME@Sema_Thera